Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC trimmed its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 42.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,037 shares of the company’s stock after selling 11,022 shares during the quarter. AQR Capital Management LLC’s holdings in Vir Biotechnology were worth $134,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Affinity Asset Advisors LLC bought a new position in Vir Biotechnology in the 2nd quarter worth approximately $1,780,000. Caxton Associates LP bought a new position in Vir Biotechnology in the 2nd quarter worth approximately $531,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in Vir Biotechnology by 491.7% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 18,959 shares of the company’s stock worth $169,000 after buying an additional 15,755 shares in the last quarter. Point72 Hong Kong Ltd grew its holdings in Vir Biotechnology by 180.6% in the 2nd quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company’s stock worth $174,000 after buying an additional 12,598 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in Vir Biotechnology by 6,402.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,624 shares of the company’s stock worth $1,679,000 after buying an additional 185,723 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

VIR has been the subject of a number of research reports. Barclays increased their price target on Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $36.80.

Insider Transactions at Vir Biotechnology

In other news, Director Janet Napolitano sold 12,190 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $7.80, for a total transaction of $95,082.00. Following the completion of the sale, the director now directly owns 11,616 shares of the company’s stock, valued at $90,604.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 15.60% of the company’s stock.

Vir Biotechnology Stock Down 1.2 %

VIR opened at $7.63 on Friday. The firm has a market cap of $1.04 billion, a PE ratio of -1.90 and a beta of 0.46. The business has a fifty day simple moving average of $7.93 and a 200-day simple moving average of $8.97. Vir Biotechnology, Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.13). The company had revenue of $3.08 million for the quarter, compared to the consensus estimate of $7.53 million. Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. The business’s revenue was down 19.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.45) earnings per share. On average, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.26 EPS for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).